Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot could help asian adults shed pounds

NCT ID NCT07668401

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 25, 2026 · Updated 5 times

Summary

This Phase 3 study tests whether a weekly injection called zenagamtide helps Asian adults with overweight or obesity lose weight safely. About 400 participants will receive either the drug or a placebo for several weeks. The main goal is to see how much body weight changes, with waist size also measured.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zenagamtide
What this could lead to
If it works, this could offer a new weekly injection to help Asian adults with overweight or obesity lose weight and reduce waist size.
What could go wrong
This is a Phase 3 trial, but results may not apply to all populations. Side effects from the injection are possible, and the drug may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    44 sites in 5 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ajou University Hospital_Family Medicine

    Suwon, Gyeonggi-do, 16499, South Korea

  • All India Institute of Medical Science (AIIMS), Guwahati

    Assam, 781101, India

  • All India Institute of Medical Sciences (AIIMS), Nagpur

    Nagpur, Maharashtra, 441108, India

  • BSES MG hospital

    Mumbai, Maharashtra, 400058, India

  • Chellaram Diabetes Institute

    Pune, Maharashtra, 411021, India

  • Christian Medical College Hospital, Vellore

    Vellore, Tamil Nadu, 632004, India

  • Diabetes Research Center, Hyderabad

    Hyderabad, Telangana, 500 082, India

  • Excel Endocrine Centre

    Kolhāpur, Maharashtra, 416008, India

  • Fukuwa Clinic_Internal Medicine

    Tokyo, 104-0031, Japan

  • GMERS Medical college and hospital

    Vadodara, 390021, India

  • Government Medical College, Kozhikode

    Kozhikode, Kerala, 673008, India

  • Grant Medical Foundation Ruby Hall Clinic

    Pune, Maharashtra, 411001, India

  • Hospital Canselor Tuanku Muhriz UKM

    Cheras, Kuala Lumpur, 56000, Malaysia

  • Hospital Melaka

    Malacca, 75400, Malaysia

  • Hospital Miri

    Miri, Sarawak, 98000, Malaysia

  • Hospital Putrajaya

    Putrajaya, 62250, Malaysia

  • Karnataka Medical College and Research Institute

    Hubbali, Karnataka, 580022, India

  • Kindai University Hospital_Department of Endocrinology, Metabolism and Diabetes

    Sakai-shi, Osaka, 590-0197, Japan

  • Konkuk University Medical Center_Endocrinology

    Seoul, 05030, South Korea

  • Kyungpook National University Hospital_Family Medicine

    Daegu, 41944, South Korea

  • Madras Diabetes Research Foundation

    Chennai, Tamil Nadu, 600086, India

  • Maharaj Nakorn Chiang Mai

    Chiang Mai, 50200, Thailand

  • Maulana Azad Medical College

    Delhi, New Delhi, 110002, India

  • Medical Corporation Shinanokai Shinanozaka Clinic_Internal Medicine

    Shinjuku-ku, Tokyo, 160-0017, Japan

  • Nirmal Hospital Pvt. Ltd.

    Surat, Gujarat, 395002, India

  • OCROM Clinic_Internal medicine

    Suita-shi, Osaka, 565-0853, Japan

  • Osmania General Hospital

    Hyderabad, Telangana, 500012, India

  • Pusan National University Yangsan Hospital_Family Medicine

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • SMS Hospital

    Jaipur, 302004, India

  • SSG Hospital, Baroda

    Vadodara, Gujarat, 390001, India

  • Seoul National University Bundang Hospital_Endocrinology

    Seoungnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital_Family Medicine

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System_Family Medicine

    Seoul, 03722, South Korea

  • Shalini Tai Meghe Hospital and Research Center

    Nagpur, Maharashtra, 441110, India

  • Shree Mahalaxmi DIATONE Institute

    Kohlapur, Maharashtra, 416001, India

  • Siriraj Institute of Clinical Research

    Bangkok, 10700, Thailand

  • Songklanagarind Hospital

    Songkhla, 90110, Thailand

  • TOTALL Diabetes Hormone Institute

    Indore, Madhya Pradesh, 452010, India

  • Thammasat Hospital_CRC

    Pathum Thani, 12120, Thailand

  • ToCROM Clinic_Internal Medicine

    Tokyo, 160-0008, Japan

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, 103-0027, Japan

  • University Malaya Medical Centre

    Lembah Pantai, Kuala Lumpur, 59100, Malaysia

  • Vijan Hospital & Research Centre

    Nashik, Maharashtra, 422005, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.